NICE publishes draft guidance for two prostate cancer treatments
8 June 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has launched public consultations on draft recommendations for two prostate cancer drugs...
List view / Grid view
News
Xultophy Phase 3b study showed statistically significant HbA1c reduction, body weight change and lower rate of hypoglycaemia versus insulin glargine
8 June 2015 | By Victoria White
Phase 3b findings show adults with T2D treated with Xultophy demonstrate statistically significant reduction in HbA1c and a lower rate of hypoglycaemia...
New study with Victoza showed improvements in blood glucose control in adults with type 2 diabetes who fasted during Ramadan
8 June 2015 | By Victoria White
New findings showed that adults with type 2 diabetes treated with Victoza experienced improvements in blood glucose control while fasting during Ramadan...
Lilly commits 780,000 vials of insulin to Life for a Child
8 June 2015 | By Victoria White
Eli Lilly and Company has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child programme...
ClickJect Pre-Filled pen provides more treatment choice for patients in the UK with rheumatoid arthritis
4 June 2015 | By Victoria White
UK patients with rheumatoid arthritis now have more choice for managing their condition with the launch of the ClickJect Pre-Filled pen...
Catabasis Pharmaceuticals announces preliminary Phase 1 data for hypercholesterolaemia product candidate CAT-2054
4 June 2015 | By Victoria White
Catabasis has announced preliminary Phase 1 clinical trial data for CAT-2054 - its candidate for the potential treatment of hypercholesterolaemia...
Blaze Bioscience announces open enrollment for Phase 1 clinical trial of Tumour Paint BLZ-100 in children with brain cancer
4 June 2015 | By Victoria White
Blaze Bioscience has announced open enrollment for the first clinical study of Tumour Paint BLZ-100 in children with brain cancer...
Exalenz Bioscience launches clinical study for breath-based detection of primary liver cancer
4 June 2015 | By Victoria White
Exalenz Bioscience has initiated a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer...
Phase 2a clinical trial results for emixustat hydrochloride published
4 June 2015 | By Victoria White
Results from a Phase 2a clinical trial of emixustat in geographic atrophy associated with dry age-related macular degeneration have been published...
AVEO receives European regulatory guidance regarding potential marketing authorisation application for tivozanib
4 June 2015 | By Victoria White
AVEO has received confirmation of support from two CHMP members following pre-submission meetings to discuss the potential submission of a MAA for tivozanib...
FDA grants Breakthrough Therapy designation to Genzyme’s olipudase alfa
4 June 2015 | By Victoria White
The FDA has granted Breakthrough Therapy designation to Genzyme’s olipudase alfa for the treatment of Niemann-Pick disease type B...
Amicus submits EU marketing authorisation application for Fabry monotherapy Galafold
3 June 2015 | By Victoria White
Amicus Therapeutics has submitted a MAA to request full approval in the EU of Galafold for Fabry patients who have amenable genetic mutations...
EC approves Helsinn’s Akynzeo for prevention of chemotherapy-induced nausea and vomiting
3 June 2015 | By Victoria White
The EC has approved Akynzeo for use in the European Union for the prevention of acute and delayed chemotherapy-induced nausea and vomiting...
EMA approves Resolor for use in men for the symptomatic treatment of chronic constipation
3 June 2015 | By
The EMA has approved Resolor for use in adults for the symptomatic treatment of chronic constipation in whom laxatives fail to provide adequate relief...
Results from Phase 2b study of CETP inhibitor TA-8995 published
3 June 2015 | By Victoria White
Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia...
